TELA Bio
TELA
32 hedge funds and large institutions have $95M invested in TELA Bio in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 6 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
16.25% more ownership
Funds ownership: 76.71% → 92.96% (+16%)
7% more funds holding
Funds holding: 30 → 32 (+2)
27% less capital invested
Capital invested by funds: $130M → $95M (-$34.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$9.68M |
| 2 |
IV
Industry Ventures
San Francisco,
California
|
+$4.81M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.54M |
| 4 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
+$2.2M |
| 5 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
+$2.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Silvercrest Asset Management
New York
|
-$4.61M |
| 2 |
AC
Armistice Capital
New York
|
-$2.23M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$190K |
| 4 |
Two Sigma Investments
New York
|
-$123K |
| 5 |
JAMONY
Jacob Asset Management of New York
Hermosa Beach,
California
|
-$107K |
TELA Hedge Fund Activity: Q2 2022 in Review
32 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in TELA Bio (TELA) for Q2 2022, worth a combined $95M — down 27% from $130M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TELA positions and 6 closed out — a net gain of 2 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Opaleye Management, adding an estimated $9.68M. The largest seller was Silvercrest Asset Management, exiting entirely with an estimated $4.61M sold.
- 32 institutional investors held TELA Bio (TELA) as of Q2 2022, up from 30 in Q1 2022.
- Funds reported $95M of TELA Bio stock for Q2 2022, down 27% quarter-over-quarter.
- 8 funds opened new TELA Bio positions in Q2 2022 and 6 closed out, a net change of +2 holders.
- The largest TELA Bio buyer in Q2 2022 was Opaleye Management, an estimated $9.68M added.
- The largest TELA Bio seller in Q2 2022 was Silvercrest Asset Management, an estimated $4.61M sold.
Based on aggregated 13F filings for Q2 2022.